With Bristol-Myers Squibb Co.'s $74bn acquisition of Celgene Corp. set to close in the third quarter – a deal that requires shareholder approval – Celgene spent its Jan. 31 earnings conference call reassuring investors that sales of its marketed drugs are growing and its pipeline programs remain on track.
Celgene Gives Reassurances That Key Products And Programs Remain On Track
Celgene's quarterly earnings call was all about reassuring investors that its products and pipeline will deliver the full value of the company's acquisition by Bristol-Myers after the deal closes in the third quarter.
More from Earnings
• By
As drugmakers update investors on first quarter financial performance, uncertainty around global trade and US regulatory oversight is likely to dominate discussions.
• By
Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.
• By
Industry lobbied for pharmaceuticals to be exempt from Trump’s sweeping US tariffs and the effort appears to have paid off. J&J, Lilly and Merck & Co. even got shout outs.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
More from Business
• By
Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.
• By
As drugmakers update investors on first quarter financial performance, uncertainty around global trade and US regulatory oversight is likely to dominate discussions.
• By
Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.